After all, the iPSCs technology provides a potential therapy for monogenic disorders, as to AD patients with mutations in APP, PSEN1, and PSEN2, shedding light on ultimate therapy of FAD by correcting these mutation. Here, PSEN2 is linked to Alzheimer disease.